Gaeta Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Gaeta Therapeutics is a private, pre-revenue biotech firm leveraging intellectual property to enhance cancer immunotherapy. Its core asset is a patent portfolio protecting the synergistic use of locally administered IL-12 with checkpoint blockers (anti-CTLA4, anti-PD1/PDL1) to treat cancers unresponsive to conventional immunotherapy. The company's business model is solely focused on out-licensing this IP through exclusive and non-exclusive agreements worldwide, with no internal R&D or clinical pipeline reported. It represents a specialized, asset-light approach to monetizing a specific combination therapy concept in the competitive immuno-oncology space.

Oncology

Technology Platform

Patent estate covering the localized delivery/expression of Interleukin-12 (IL-12) via protein, nucleic acid, or viral vectors in combination with systemic checkpoint blockade (anti-CTLA4, anti-PD1/PDL1).

Opportunities

The significant unmet need in immuno-oncology, where most patients don't respond to checkpoint inhibitors alone, creates a large addressable market for effective combination therapies.

Gaeta's IP offers a validated biological pathway (IL-12) to sensitize tumors, presenting a licensing opportunity for companies seeking to enhance their immuno-oncology portfolios without internal discovery.

Risk Factors

The company's value is entirely concentrated in a single patent portfolio, making it vulnerable to invalidation challenges or the development of successful work-around therapies.

Its success is completely dependent on third-party licensees, who may prioritize other combination approaches, leaving Gaeta with no revenue if licensing deals are not secured.

Competitive Landscape

The field of immuno-oncology combinations is intensely competitive, with numerous companies and academic groups exploring IL-12 delivery alongside other agents. Gaeta competes with entities developing proprietary IL-12 variants, gene therapies, and oncolytic viruses, as well as with broader combination strategies targeting different cytokines or immune pathways.

More companies in Immunotherapy / Immuno-Oncology →More companies in United Kingdom →